Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies
(5h)
Cell therapy biotech Obsidian leverages Galera reverse merger to go public
(17h)
Click Therapeutics cuts staff after commercial deal restructuring
(18h)
Astellas to close stem cell unit’s Seattle site, with layoffs incoming
(18h)
Takeda terminates mRNA research pact with Japanese drug discovery specialist
(18h)
Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
(18h)
Australia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drug
(19h)
Stryker makes a buy as Avalon to go private in a spate of medtech M&A deals
(20h)
Alamar Biosciences files for IPO amid opening life sciences funding window
(1d)
Lilly makes preclinical ADC specialist CrossBridge its latest acquisition in vague $300M deal
(1d)
FDA urges clinical trial sponsors to report the results of their studies
(1d)
Kailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assets
(1d)
Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
(1d)
AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
(1d)
Retractable Technologies trims staff to save $2.2M annually as tarriffs bite
(1d)
Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
(1d)
Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial
(1d)
BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
(2d)
Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix
(2d)
Harbinger Health raises $100M for new suite of blood-based cancer detection tests
(2d)
BioPharma Dive
Travere wins long-awaited approval for kidney disease drug
(16h)
J&J leans on Tremfya, cancer drugs to overcome Stelara losses
(17h)
Lilly boosts ADC portfolio with CrossBridge Bio deal
(18h)
Novo teams with OpenAI; Ideaya gets muted response to eye drug data
(19h)
Spyre drug for inflammatory bowel disease shows promise in early study
(1d)
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma
(1d)
Revolution pancreatic cancer drug nearly doubles survival in key trial
(1d)
Connected medical devices: Smarter care starts here
(2d)
Rethinking dermatology trial design for late-stage success
(2d)
FDA again spurns Replimune melanoma drug
(4d)
Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors
(4d)
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
(4d)
Women have awaited a revolution in menopause. It hasn’t arrived.
(4d)
Invivyd reveals plans to test an antibody drug against measles
(5d)
Chasing a tough-to-treat lung disease, Avalyn plans an IPO
(5d)
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk
(5d)
Sidewinder secures $137M to advance ‘precision’ ADCs
(6d)
With 3 quick buyouts, Gilead leans into its latest transformation
(6d)
Activist investor revives campaign to overhaul Novavax board
(6d)
Jeito Capital, prominent biotech investor, raises $1.2B for next fund
(6d)
Endpoints News
FDA asks for more data on Lilly’s Foundayo to assess heart, liver risks
(14h)
Replimune looks ahead as repeat CRL speeds the company's decline
(15h)
Revolution Medicines leads latest wave of stock offerings, totaling $1.5B
(17h)
Endpoints biopharma sentiment survey for Q2 2026
(17h)
Harbinger raises $100M; Astellas to close Seattle site
(17h)
J&J increasingly confident it can manage Stelara cliff, but work remains
(17h)
Eli Lilly to pay up to $300M for cancer biotech CrossBridge Bio
(20h)
Parker Institute doubles down on cancer vaccines as part of ongoing reboot
(21h)
FDA approves Travere's Filspari as first drug for the kidney disease called FSGS
(23h)
Click Therapeutics cuts 27% of workforce after $50M raise
(1d)
White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says
(1d)
FDA narrows in on search for new biologics and vaccines leader
(1d)
Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promise
(1d)
Neomorph raises $100M for molecular glues; Spyre's ulcerative colitis data
(1d)
Regeneron wades into radiopharma through $40M upfront deal with Telix
(1d)
BioNTech's HER2 ADC succeeds in Phase 2 study, FDA filing planned
(1d)
Revolution Medicines' pancreatic cancer drug doubles survival time in Phase 3
(1d)
Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial
(1d)
Seaport and Hemab file for IPOs, with Kailera expected to price soon
(2d)
GSK plans five Phase 3 studies for gynecological cancer ADC from Hansoh
(2d)
BioSpace
Could biotech layoffs push life sciences talent to go global?
(1h)
5 biopharma M&A deals where the workforce was the prize
(4h)
Deep dive: Checking in with the FDA
(4h)
FDA bolsters bespoke therapy framework with new draft safety guidelines
(14h)
50 employees impacted as Astellas closes Universal Cells' Seattle office
(17h)
Bonus: Q1 2026 Job Market Update
(18h)
With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026
(18h)
Lilly investing billions to prepare for overseas oral GLP-1 launches
(19h)
Lilly wants to bridge cancer care gap with $300M ADC biotech buy
(19h)
On steadier ground, pharma heads into Q1 earnings with deals top of mind
(20h)
Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease
(21h)
Kailera eyes record $533M+ IPO to play in competitive obesity space with Chinese drugs
(22h)
FDA asks 2,200 drug developers to make trial results public, ramping up transparency push
(22h)
Why Companies Should Pursue True Patient-Centricity
(1d)
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial
(1d)
USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns
(1d)
Allogene stock sails after CAR T clears residual lymphoma in early data cut
(1d)
Revolution rises 40% as pancreatic cancer drug doubles survival
(1d)
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy
(1d)
AbbVie enters world of pain in up to $715M deal with China’s Haisco
(1d)
STAT News
Congress returns to a packed health care agenda
(15h)
FDA pressures drugmakers to report trial results
(18h)
Hospitals offer chatbots to fight off ChatGPT
(19h)
We’re reading about an FDA push for trial transparency, a Novo-OpenAI deal, and more
(19h)
A fluoride shortage for some U.S. water systems
(20h)
For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option
(1d)
A top WHO official confronts Iran war fallout, and weighs bid for an even bigger role
(1d)
Dana-Farber CEO talks untangling from Mass General Brigham and building new cancer hospital
(1d)
My brother can’t access a just-approved breakthrough drug for his rare disease
(1d)
Maryland state affordability board sets its first price cap for a medicine
(1d)
FDA pushes drugmakers to report missing clinical trial results
(1d)
Federal judge tosses California No Surprises Act lawsuit against HaloMD
(1d)
Access granted: CMS greenlights hundreds of participants for chronic care experiment
(1d)
Trump goes soft on insurance, and a medical underwriting chart
(1d)
GSK advancing ovarian cancer drug mo-rez
(1d)
On positioning nurses as health experts
(1d)
We’re reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more
(1d)
Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill
(1d)
Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients
(1d)
Spyre Therapeutics IBD drug shows promise in early trial
(1d)
BioPharma Trend
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(17h)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(5d)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(5d)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(1w)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2w)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(2w)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(2w)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(2w)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(3w)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(3w)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(3w)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(3w)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(3w)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(3w)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(3w)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(3w)
AI-Guided Brain Implant for Memory Loss Gets FDA Breakthrough Status
(4w)
Dyno Launches Open-Source Agentic Protein Design Suite at GTC 2026
(4w)
AlphaFold Database Now Includes Protein Pair Interactions
(4w)
Basecamp Launches Trillion Gene Atlas Targeting Over 100 Million Species for Better AI Training Data
(4w)
Drug Channels
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update
(21h)
Informa Connect’s Life Sciences Pricing & Contracting USA
(2d)
The Net Pricing Revolution in the Drug Channel: What’s Deflating the Gross-to-Net Bubble (rerun)
(4d)
The FTC Blows Up Express Scripts’ PBM Model—and Launches the Net Pricing Drug Channel (rerun)
(5d)
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
(6d)
Drug Channels News Roundup, Mid-April 2026: Vertical Integration & MLR Games, Copay Maximizers, Hospital Price Chaos, and One Big Drug Channel Family
(1w)
The Big Three PBMs’ 2026 Formulary Exclusions: MFP, Private Label Biosimilars, and Direct-to-Patient Threats for PBMs (rerun)
(1w)
Building What’s Next: Join Industry Leaders to Shape Access and Affordability Trends Ahead of Asembia AXS26
(2w)
Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo
(2w)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments
(2w)
The Rare Journey Needs a Special Pharmacy Partner
(3w)
Reflections and Photos from the Drug Channels Leadership Forum 2026
(3w)
NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
(3w)
Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand
(4w)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies
(4w)
Reshaping Patient Affordability: The Power of Expertise and Agility
(1mo)
PBM Industry Update 2026: Trends, Challenges, and What’s Ahead (NEW Live Video Webinar)
(1mo)
Time to Evolve: Hubs Flex to New Demands
(1mo)
Preorder Now: DCI’s 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
(1mo)
Beyond DTP 2.0: How Flexible Direct-to-Patient Programs Power Best-In-Class Patient Experiences
(1mo)
European Biotechnology Magazine
Adcendo banks US$75m to push ADC pipeline forward
(1h)
Clean Food Group to scale yeast-based oils with £4.5m in the bank
(23h)
BioNTech reports promising Phase II data for uterine cancer ADC
(3d)
Basilea lands US$6m CARB X boost for novel antibiotic
(6d)
SLAS Announces the Cohort for Innovation AveNEW at SLAS Europe 2026
(6d)
Jeito Capital raises record US$1.2bn to bankroll European biopharma’s next generation
(7d)
Gilead acquires German ADC specialist Tubulis in US$5bn deal
(1w)
Portugal’s biotech industry is growing up
(1w)
The rollercoaster ride stopps and danish IO Biotech goes bust
(2w)
French AI: 20 million funding for Generare to find better data in nature
(2w)
Lilly moves deeper into sleep medicine with up to $7.8 billion Centessa deal
(2w)
Where Life Science Scales in Basel
(2w)
Something of a shopping spree: Novartis to acquire US-based Excellergy for up to $2bn
(2w)
Europe’s pivotal choice: Vaccination is health security
(2w)
10 European Startups to watch in 2026
(2w)
Ysios Capital launches InceptionBio: €100m for Spanish biotech spinouts
(3w)
The European CDMO Model, Powering Biologics Innovation
(3w)
EIF starts €15bn fund-of-funds for scaling European tech companies
(3w)
TenBoron lands €7.6m EU grant for precision radiotherapy trials in hard-to-treat cancers
(3w)
Immutrin secures £65m Series A for amyloid-removing heart therapy
(3w)
Drug Hunter
BHV-2100
(17h)
orforglipron
(1d)
Module 3 Quiz
(1d)
Daraxonrasib (RMC-6236): The 2025 Molecule of the Year
(5d)
relacorilant (CORT125134)
(5d)
More Firepower Per Molecule: Bispecific and Dual-payload ADCs Push for Greater Efficacy
(6d)
TNO155
(1w)
Module 3, Section 2: Quality not Quantity
(1w)
quemliclustat
(1w)
soquelitinib
(2w)
asundexian
(2w)
A Deep Dive into INN Proposed List 134
(2w)
AZD5004
(2w)
avutometinib and defactinib
(2w)
Module 3, Section 1: HitID Screens
(2w)
February 2026
(3w)
February 2026 Patent Highlights
(3w)
ACS Spring 2026 First Time Disclosures
(3w)
TL1A Inhibition in IBD: Deamplifying Biology for Clinical Proof-of-Concept
(3w)
QPX7728
(3w)
Labiotech.EU
Can phage therapy answer the booming antibiotic resistance problem?
(19h)
Amgen pipeline’s next growth cycle: replacing its old blockbusters
(1d)
Top biotech deals in March 2026
(4d)
Multi-agent AI delivers reliable and scalable insights for single-cell omics
(5d)
Extracellular vesicles: a growing pipeline still searching for validation
(6d)
The biggest biotech funding rounds in March 2026
(1w)
The future of cell & gene therapy: Key trends to watch
(1w)
Nionyx Bio’s kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight
(2w)
Portugal: will the life science sector see upswing amid funding worries?
(2w)
Six biotech companies in Berlin to watch in 2026
(2w)
Next-generation allosteric modulators: A glance at the biotech pipeline in 2026
(2w)
Biotech in New Jersey, seven companies leading the charge
(2w)
BIO-Europe Spring 2026: partnership event brings funding hope to biotechs
(3w)
HaemaLogiX – precision immunotherapy for multiple myeloma
(3w)
GSK’s two-speed strategy: broad sourcing and selective bets
(3w)
Seven T cell engager companies you should know about
(3w)
The six biotech companies in Portugal you should know about in 2026
(3w)
After the drought, biotech IPO activity begins to pick up in 2026
(4w)
How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
(4w)
Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs?
(4w)
Bio IT World
PARTAGE Method Reveals Genome Regulation in Single Approach
(1d)
CAS Releases Agentic Tool for Literature Discovery
(5d)
'Mini-brain' Model Explores Concussion's Effects at Cellular Level
(6d)
‘Humble’ AI Reveals When It is Uncertain in Diagnoses
(1w)
Inductive Bio on a Winning Streak With ADMET Predictions
(2w)
From Data to Discovery: Inside the Bio-IT Hackathon
(2w)
Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life
(2w)
The Value of Prediction, and Cost of Success, in Drug Hunting
(3w)
Follow the Money: Brain-Computer Retinal Implant, Expansion of Alzheimer’s Platform, Migraine Therapies
(3w)
Verily, Samsung Collaborate, Improving AI Trustworthiness, FDA Approval for PathAI
(3w)
PerturbAI Launches with CRISPR Atlas
(4w)
piRNAs Emerge as a New Frontier in Longevity
(4w)
Open Source ‘Floats All Boats’ in AI-Driven Drug Discovery
(4w)
Ancient Mushroom, Modern Medicine: Paul Stamets Says Agarikon Mycelium May Be Key to Fighting Viral Pandemics
(1mo)
Russia to Expand National Genetics Database to Ensure Treatment for Various Ethnic Groups
(1mo)
How HPC Systems Are Making Things Easier
(1mo)
Infant Microbiome Atlas Makes Case for Region-Specific Probiotics
(1mo)
MIT Develops Biodegradable “Smart Pill” to Track Medication Adherence
(1mo)
Lee Hood’s Persistent Plan to Reinvent Medicine From the Ground Up
(1mo)
Illumina Acquires SomaLogic, Sanofi’s New CEO, Parse Bioscience’s New Product Line
(1mo)
GEN News
Engineered Miniature CRISPR Boosts Gene‑Editing Efficiency in Human Cells
(9h)
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients
(12h)
Regeneron, Telix Launch Up-to-$4.3B Cancer-Focused Radiopharma Drug, Diagnostic Collaboration
(13h)
GLP-1 Drug Improves Liver Health Independent of Weight Loss, Mouse Study Finds
(13h)
AWS Launches Amazon Bio Discovery Agentic AI to Accelerate Drug Development
(17h)
From Colossal to Chickens: The Scientists Behind Neion Bio’s Biologics Platform
(18h)
Sex-Related Differences in Immune System Aging May Impact Disease Susceptibility
(1d)
Salk to Lead $41.3M ARPA-H Effort to Advance Sonogenetics Therapies
(1d)
AACR 2026: Professional Awards Acknowledge Community’s Contributions to Cancer Research
(1d)
Advancing Fully Walkaway Automation in Genomics Workflows
(1d)
Neural Mechanism Underlying Sensory Behavior Revealed in C. elegans
(1d)
Building the Genome Grid
(1d)
StockWatch: IPO Market Shows Sign of Life with Avalyn Filing
(2d)
Epigenetics at Birth Links Microbiome to Neurodevelopment, Potentially ASD and ADHD
(4d)
First Detailed Insight into Bornavirus Nucleoprotein–RNA Complex Reveals Unique Assembly
(4d)
Cryo-EM Structural Biology Facility Opened in San Diego by FairJourney Bio
(4d)
Drugs from a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
(4d)
Cancer Drug Shortfalls Tied to How BET Inhibitors Hit BRD2 and BRD4 Differently
(5d)
BBB Access Route via Proteomic Vascular Mapping
(5d)
DNA Uptake in Cholera May Increase Defense Mechanisms
(5d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(3w)
Understanding High-Risk Essential Thrombocythemia
(3w)
Son’s Decision to Donate Gave His Father a Second Chance
(4w)
Functional Precision Medicine Advances Brain Tumor Care
(4w)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(4w)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(4w)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(4w)
How Honest Conversations Strengthened a Couple After Cancer
(4w)
Cardiac Health in Cancer Survivors: A Growing Need
(4w)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(4w)
Understanding Mental Health Referrals in Cancer Care
(4w)
Breast Cancer Early Detection: A Bold and Breastless Survival Story
(4w)
Talzenna Plus Xtandi Delays Prostate Cancer Progression
(4w)
Evolving Treatment Strategies Are Reshaping mCRPC Care
(4w)
Pimicotinib Shows Early, Strong Tumor Response in Tenosynovial Giant Cell Tumors
(4w)
Life After Liver Cancer: A Couple’s Journey of Recovery and Care
(4w)
Why This Breast Cancer Survivor Chose "Flatness" After Implants
(4w)
NCCN Guidelines Expand Options for Certain Bladder Cancer Patients
(4w)
FOURLIGHT-1 Study Data Support Atirmociclib for HR+/HER2- Breast Cancer
(4w)
Key Updates in Bladder, Kidney and Prostate Cancer from Experts
(4w)
Contract Pharma
FDA Approves Travere’s Filspari for Treatment of Focal Segmental Glomerulosclerosis
(12h)
Labcorp Unites With AWS and Datavant on AI Platform to Accelerate Alzheimer’s Research
(14h)
BostonGene, ImmunoGenesis Partner to Accelerate Development of Immune Checkpoint Inhibitor
(16h)
Parabilis Medicines Updates Executive Leadership Team
(17h)
Vasa Therapeutics to Use Eli Lilly AI Platform in Drug Discovery Collaboration
(17h)
Valo Health Taps Dr. Chris Anagnostopoulos as Chief Causal AI Officer
(17h)
Kincell Bio Expands Research Triangle Park, North Carolina Facility
(18h)
CS Analytical Appoints Jennifer Roark as Director of Scientific Affairs
(19h)
Vetter Expands Global Clinical Manufacturing Network in U.S. and Europe
(19h)
DWK Life Sciences Names New Group CEO
(19h)
Abcam Launches Next-Gen ELISA, Wider Dynamic Range Delivers Results in Less Time
(20h)
DDL to Showcase its Drug-Delivery Testing Capabilities
(1d)
OXB Launches Fast-Track Offering to Accelerate Viral Vector Development and Manufacture
(1d)
Switchback Medical Signs Lease for Facility in Costa Rica Free Trade Zone
(1d)
Neomorph Inc. Closes $100M Series B Financing
(1d)
Regeneron, Telix Enter Strategic Radiopharma Collaboration
(1d)
Haisco Grants AbbVie Exclusive Rights to Advance Novel Pain Medicines
(1d)
Thermo Fisher Scientific, HealthVerity Partner to Expand Real-World Data Capabilities
(1d)
Apotex Gets First US Tentative Approval for Generic Semaglutide Injection
(4d)
Circio Completes Oversubscribed Financing, With Proceeds to Accelerate Circular RNA Platform
(4d)
Pharma Times
Transgene completes randomisation in phase 2 trial of tg4050
(2d)
Bayer wins MHRA approval for Kerendia in heart failure
(2d)
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
(5d)
Kainova expands DT 7012 trial into Europe
(5d)
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
(1w)
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
(1w)
FDA approves new high dose Spinraza regimen for SMA
(2w)
Viridian reports positive results from elegrobart phase 3 trial
(2w)
Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
(2w)
Kygevvi approved in Europe as first treatment for TK2d
(2w)
Tozorakimab shows significant benefit in two major COPD trials
(2w)
Daratumumab becomes first oncology injectable approved for patient administration
(2w)
Laigo Bio completes final close of €17m seed financing round
(3w)
Axplora announces expansion as newest part of $60m API investment programme
(3w)
DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
(3w)
Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
(3w)
Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
(4w)
Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
(4w)
Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
(4w)
Atrogi begins dosing first subjects in human trial of ATR-258
(4w)
Medcity News
Heartflow Sues Cardiac AI Rival Cleerly Over Alleged IP Theft
(8h)
Vida Health Teams Up with ŌURA to Provide More Personalized Metabolic Care
(9h)
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease
(10h)
5 of the Top 10 U.S. Health Systems Are Moving to This New Health IT Category. Here’s Why.
(15h)
Why Synthetic Data is the Antidote to Clinical Trials
(18h)
Clinical Supply Chain Hits Its AI Turning Point
(19h)
Hospital Margins Squeeze as Costs Outpace Revenue Growth
(1d)
Report: Growth in MA Is Associated With Lower Total Medicare Spending
(1d)
Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial
(1d)
The AI Value Gap and Why Validation is a Practical First Win for Life Sciences
(1d)
Trust Before Triage: Why I Let the Patient Help Write the Agenda
(1d)
‘A Significant Assault on Our Health’: Healthcare Policy Leaders Condemn Trump’s Budget Proposal
(2d)
Two New Takes on Making a Type of Targeted Cancer Therapy Even Better
(2d)
Inside The DOJ’s Hospital Contracting Crackdown: What Message Are the Feds Sending?
(2d)
What ‘The Pitt’ Gets Right About Emergency Medicine — and What It Reveals About Healthcare IT
(2d)
ACA Stress Test: Four Key Takeaways from This Year’s Open Enrollment
(2d)
How TEFCA Is Speeding Up Disability Benefits Determinations at Hospitals
(4d)
Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer
(4d)
With $100M Raise, Chapter Targets Medicare Mismatches for Seniors
(4d)
Know Your Patient: How Technology Can Help Health Care Providers Dramatically Improve One Key Aspect of the Patient Experience
(4d)
Chemical & Engineering News
Carter to become next CEO of Dow
(12h)
Business Watch: Borouge International emerges; Regeneron, Telix link for radiopharma
(14h)
Satellite data reveal rising methane levels
(15h)
Academic freedom declines in US and 49 other countries, survey finds
(15h)
Memory Lane: From the steering committee to global researcher, professor, and mentor
(15h)
Mouse neurobehaviorist by day; research integrity watchdog by night
(22h)
Simple bath readies lithium-metal anodes for long-range EVs
(1d)
Smita Mohanty named 2026 Oklahoma Chemist of the Year
(1d)
Chemistry in Pictures: Everything that a cell is
(1d)
Hidden antivirals discovered in a plant-derived supplement
(1d)
Comment: Remastering local sections
(1d)
US and French rare earth companies partner in bid to catch up with China
(4d)
Trump administration withdraws on fighting for NIH cap on indirect costs
(4d)
Expansion microscopy tool kit corrects distortion of blown-up cells
(4d)
C&EN weekly chemistry news quiz, April 10
(4d)
An implantable living pharmacy produces drugs in the body
(4d)
Apr 10 Policy Watch: HHS updates criteria for selecting vaccine-committee members
(4d)
Data discovered in surprising places
(5d)
With cash to burn and patent cliffs looming, pharma giants are buying more biotechs
(5d)
Obituary: Thomas L. Penner
(5d)
The Pharma Letter
Neomorph secures $100M Series B to scale molecular glue degrader pipeline
(48m)
US govt investments in Gilead’s lenacapavir for HIV prevention
(1h)
CrossBridge Bio latest ADC firm to be snapped up in Lilly deal
(16h)
FDA draft guidance on genome editing safety standards
(18h)
Positive Phase III results for Jaypirca in new CLL group
(18h)
Positive Phase III results for Jaypirca in new CLL group
(18h)
MHRA approves new high dose regimen of Spinraza
(19h)
Travere’s Filspari wins landmark US approval
(19h)
Adcendo completes $75 million Series C financing
(21h)
SynOx Therapeutics heading for FDA filing for emactuzumab in TGCT
(21h)
OpenAI partnership places Novo Nordisk at ‘forefront of AI transformation’
(22h)
Indian generics shake up GLP-1 market as Eli Lilly loses ground
(22h)
Russian drugmaker Binnopharm hopes to gain control over Polpharma’s Akrikhin
(23h)
Laigo Bio strengthens team with CSO and advisory board appointments
(1d)
Laigo Bio strengthens team with CSO and advisory board appointments
(1d)
Haisco Pharma strikes deal with AbbVie to develop novel pain medicines
(1d)
Regeneron and Telix reveal radiopharm collab
(1d)
Revolution Medicines' daraxonrasib shows unprecedented overall survival
(1d)
Pioneering Lotte Bjerre Knudsen to leave Novo Nordisk
(1d)
Russia begins more active cancelling of tenders for drugs awaiting cheaper generics
(1d)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(4w)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(4w)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(4w)
Treating Triple Negative Breast Cancer in the Frontline Setting
(4w)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(4w)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(4w)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(4w)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(4w)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(4w)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(4w)
PSMA PET Applications in Prostate Cancer Management
(4w)
FDA Confirms Potential Accelerated Path for Givastomig in GE Cancer
(4w)
Deescalation vs Intensification: How to Ensure Patients Get the Treatment They Need
(4w)
Deescalation Therapies in Breast Cancer Treatment
(4w)
Prospective Data Support i31-SLNB Test to Guide Biopsy Use in Melanoma
(4w)
LITESPARK-011 Signals Shifting Paradigm in RCC
(4w)
Biomarkers, Oncolytic Viruses, and the Promise of Personalized Treatment for Glioblastoma
(4w)
Priority Voucher Leads to Rapid Approval of Teclistamab in Myeloma
(4w)
How ctDNA Testing is Changing Lymphoma Treatment
(1mo)
Symptom Burden, Functional Status, and Ongoing Challenges in Progressive Small Bowel Neuroendocrine Tumor
(1mo)
MedWatch
Kailera and Alamar aim for billion-dollar valuations in new IPOs
(19m)
Zealand Pharma appoints US-based investor relations head
(37m)
Amazon launches AI tool for drug development
(1h)
Gubra scraps development of hyped sleep aid: Professor cites cost
(1h)
Eli Lilly to acquire biotech firm for up to USD 300m
(1h)
Johnson & Johnson beats expectations on strong cancer drug sales
(19h)
Diamyd Medical halts phase III trial of diabetes drug candidate
(19h)
Johnson & Johnson's Darzalex sales outperform expectations
(20h)
New capital injection bolsters IPO plans for Danish biotech firm
(21h)
Jeito Capital earmarks millions of euros for Danish biotech Adcendo
(21h)
Eli Lilly tests GLP-1 candidate to treat addiction in four clinical trials
(22h)
UK approves Novo Nordisk pen for high-dosage Wegovy
(23h)
Media: LEO Pharma advances IPO preparations with bank appointments
(23h)
Genmab's cancer candidate does not increase risk of side effects in combination treatment
(1d)
Goldman Sachs sees significant potential in Demant
(1d)
Novo Nordisk joins with OpenAI to develop new treatments
(1d)
US biotech seeks quick FDA approval after improved survivability with cancer candidate
(1d)
Copenhagen Infrastructure Partners sells battery storage project to Palisade Investment Partners
(1d)
Regeneron signs radiopharma agreement Telix worth up to USD 2.1bn
(1d)
Biontech prepares FDA application after strong phase II results in endometrial cancer
(1d)
In The Pipeline
Answers and Reasons and Knowing and Thinking
(12h)
Predicting Antibody Binding: No Champagne Just Yet
(1d)
Consider the Selfish Ribosome
(4d)
New Bond Formations Just Keep On Coming
(6d)
Ah, Peptides. Where to Begin?
(1w)
A New Opioid Agonist?
(2w)
Say "Chameleonicity" Three Times Fast. Or Read This Post.
(2w)
Right Through the Skull
(2w)
Revving Up LNP Delivery
(2w)
The Latest CAR-T Work
(3w)
Fentanyl's Membrane Behavior
(3w)
Set Phasers to "Kill". No, Not Those Phasers.
(3w)
AI-Predicting Compound Affinity. We Aren't There Yet.
(3w)
From Gut Bacteria Up to the Brain
(4w)
Beneficial Effects From the Liver to the Brain
(4w)
Now That's a Target-Guided Screen
(4w)
The Best Weapon Yet Against Sleeping Sickness
(4w)
Nitrogen, Ammonia, and the Strait of Hormuz
(1mo)
In Cells and Outside of Them
(1mo)
A Unique Situation for UniQure
(1mo)
Pharmaphorum
FDA renews criticism of trial sponsors over transparency
(20h)
Novo Nordisk partners OpenAI on R&D "transformation"
(21h)
Travere claims first FDA OK in rare kidney disease FSGS
(22h)
Revolution rockets on strong pancreatic cancer data
(23h)
Alamar, Hemab, Kailera, and Seaport advance IPOs
(1d)
IDEAYA/Servier PKC drug aces uveal melanoma trial
(1d)
AI could spare bowel cancer patients from unneeded treatment
(1d)
NICE update doubles eligible patients for AZ's Lokelma
(1d)
Data backs GSK's ovarian cancer blockbuster hopes
(2d)
FDA hands another rejection to Replimune's melanoma therapy
(2d)
Senju launches first-in-class dry eye disease drug in Japan
(4d)
Diagnostics lag is holding back new therapies, says study
(4d)
Chinese trial backs base-editing drug for thalassaemia
(4d)
Roche places a $1bn bet on C4T degrader-antibody conjugates
(5d)
Boehringer transfers schizophrenia DTx selling rights to Click
(5d)
Pulmonary fibrosis drug developer Avalyn files IPO
(5d)
NHS risks missing out on independent prescriber benefits
(5d)
AbbVie tries a new approach in 340B programme battle
(5d)
23andMe study explains variable results with obesity drugs
(6d)
Syneron raises $150m for macrocylics, and other financings
(6d)
Drug Discovery Weekly
Antibody discovery company opens cryo-EM facility in San Diego
(39m)
Laigo Bio announces new CSO as part of board appointments
(16h)
eBook: The Full Guide to Precision Medicine
(19h)
DDW Highlights: 14 April 2026
(20h)
Combo treatment new SOC in platinum-resistant ovarian cancer
(20h)
B7-H4-targeted ADC shows 62% response rate in ovarian cancer
(21h)
NEJM data support Takeda’s treatment for ITP
(22h)
Register now for Swiss Biotech Day 2026
(22h)
iBio initiates Phase I trial for weight loss antibody
(1d)
ReAlta secures $40m to advance peptide for newborn brain injury
(1d)
First-in-class TACC3 inhibitor for solid tumours shows 80% CBR
(1d)
Incyclix Bio raises extra $5m to advance cancer treatment
(2d)
Kainova Therapeutics doses first patient with cancer monotherapy
(2d)
This week in Drug Discovery (6 – 10 April)
(4d)
Collaboration to advance AAV production enhancers
(4d)
Chemify’s drug discovery platform validated by papers
(5d)
Designing scalable psychedelic therapies for treatment‑resistant depression
(5d)
Oxeia surpasses funding goal for concussion therapy
(5d)
Gene therapy could eradicate tumours in brain cancer
(5d)
Research uncovers previously unknown recessive condition
(5d)
HIT Consultant
The Clinical Resolution Gap: Why AI Can’t Fix Broken MSK Care Platforms
(1h)
Wavelet Medical Secures $7M to Scale AI Fetal Brain Monitoring Globally with Aegis Ventures
(17h)
Finding the Right Five Percent: How Machine Learning Is Reshaping Care Management
(1d)
Ultralight Raises $9.3M to Launch AI-Native Operating System for Healthcare
(1d)
The AI Arms Race: Why PHTI Warns Healthcare ‘Bot Wars’ Are Inflating Medical Costs
(1d)
ModMed Expands Multi-Year Cloud Agreement with AWS to Scale Healthcare AI Solutions
(1d)
symplr Appoints Former Edifecs Executive Venkat Kavarthapu as CEO
(1d)
The Push for Side-by-Side Prescription Pricing in EHR Workflows
(2d)
Death by a Thousand Vendors: Solera Report Reveals The Hidden Costs of Digital Health
(4d)
Qventus Report: 94% of Healthcare CIOs Say AI Delays Create Competitive Disadvantage
(4d)
The Perioperative AI Reality Check: Why Hospital Tech Fails Without Clinician Co-Design
(4d)
EBSCO Clinical Decisions Report: 80% of Clinicians Trust Evidence-Based AI Tools
(5d)
J.D. Power: Why Medicare Advantage App Usage is Plummeting While Commercial Adoption Soars
(5d)
Amazon Pharmacy Partners with Eli Lilly to Offer Foundayo GLP-1 with Same-Day Delivery
(5d)
Luminai Secures $38M, Inks Enterprise AI Partnership with Cleveland Clinic
(5d)
Click Therapeutics Secures $50M to Commercialize Schizophrenia Digital Therapeutic
(5d)
Talkiatry Launches Talkiatry Connect for Cloud-Based EMR Psychiatric Referrals
(5d)
eClinicalWorks Launches Production Support for CMS ‘Kill the Clipboard’ Initiative
(5d)
Mount Sinai Unveils Real-Time Intraocular Pressure Monitoring in Glaucoma Surgery
(5d)
M&A: LivTech Acquires Alora Healthcare Systems to Expand Post-Acute Care Platform
(5d)
Insights: Pink Sheet
Prolonged Iran Ports Blockade Risks Drug Shortages, Wider Supply Chain Woes
(3h)
US FDA To Clarify Plausible Mechanism Framework With Genome Editing Guidances, Workshop
(11h)
US FDA’s Literature-Based Leucovorin Approval May Offer A Rare Disease Template
(11h)
Does FDA Untitled Letter For Adcetris Facebook Ads Signal Start Of Social Media Crackdown?
(15h)
US Tariffs To Hit European Pharmaceutical SMEs Disproportionately
(19h)
EMA Aligns With US On Severe Liver Injury Warning For Angelini’s Ontozry
(20h)
New CBER Director Candidate Could Signal Industry Cred Important Again
(1d)
US FDA Wants Sponsors to Offer Real Plans For Pediatric Cell/Gene Therapy Trials
(1d)
More Tariff Uncertainty For Chinese Companies with US FDA-Approved Drugs
(1d)
US FDA’s CDER, CBER Continue Hiring Staff, But More Continue To Leave
(1d)
Iran War: How Companies Can Mitigate Higher Costs And Supply Chain Disruption
(1d)
Regulatory Alignment Helps Cereno Chart Faster, Cheaper Route For CS014
(1d)
US FDA Defends Review Consistency In Second CRL For Replimune’s RP1
(4d)
Plausible Mechanism Case Studies: Why US FDA Guidance Matters
(4d)
Pink Sheet Podcast: Leucovorin’s Resurrection, PhRMA’s Leadership Change
(4d)
Estonia Steps Into EU Race To Accelerate Clinical Trial Approvals
(4d)
Canada’s HTA Agency Launches New Funding To Strengthen Rare Disease Registries And RWD
(4d)
UK-US Trade Deal: Zero Tariffs On UK Exports And Possible MFN Relief For UK
(4d)
India’s High-Stakes Oral Semaglutide Battle And Novo’s ‘SNAC’ Wall
(4d)
US Pharma Tariffs – Exemptions Need More Clarity, Impact Varied
(5d)
BioXconomy
Beyond Redaction: Governing Confidential Information in an Era of Expaning Transparency
(1d)
Thermo Fisher expands RWD with HealthVerity deal
(13h)
Regeneron and Telix ink $2.1bn partnership to advance radiopharma therapies
(17h)
Fortrea debuts AI trial tech to enhance drug RD
(17h)
Eyes on Asia: Takeda, Insilico, Oricell
(23h)
Seaport and Hemab set to go public amid biotech IPO resurgence
(1d)
Cancer under siege: mRNA therapy thwarts pancreatic tumor immune evasion
(1d)
Sidewinder secure $137m Series B for oncology therapeutics
(2d)
Avalyn Pharma eyes IPO to fund Phase III trials of inhaled respiratory drugs
(4d)
Stipple Bio step onto the scene with $100m Series A
(5d)
Rising tides: Neuland appoints CEO to lead firm’s 'aggressive' peptide expansion phase
(5d)
Study reveals 6.7% of global clinical trials affected by Middle East disruption
(5d)
How Bristol Myers Squibb prepared for Medicare price talks
(5d)
340B and Medicaid monitoring in pharma
(5d)
Building a nonprofit pathway for lifesaving gene therapies
(5d)
How FemTech Portugal is building a women’s health ecosystem
(6d)
Jeito banks $1.2bn to support smaller biopharma companies
(6d)
BioNTech to shut down vaccine manufacturing facility in Singapore by 2027
(6d)
Neurocrine acquires Soleno in $2.9bn Prader-Willi therapy deal
(6d)
From Shanghai to the world: How Asia is leading global biopharma collaboration
(1w)
BioCentury
Remembering Sofinnova’s Denis Lucquin, father of French biotech
(7h)
Novartis’ Narasimhan joins Anthropic board
(7h)
Zentalis leads movers in trio of ovarian cancer updates
(9h)
Psoriasis paves the way for next-generation TYK2 inhibitors in autoimmunity
(11h)
FDA’s FIH plans. Plus: billion-dollar deals, funds — a BioCentury podcast
(1d)
RevMed’s pancreatic cancer win strengthens the case for targeting RAS(ON)
(1d)
Biotech executive, combative conservative Hemmati may head CBER
(1d)
IPO queue grows as Seaport, Hemab line up NASDAQ offerings
(1d)
Regeneron enters radiotherapy, Gilead buys another biotech, and more: Deals Report
(1d)
Fibrosis company Avalyn seeks NASDAQ listing amid volatility: Finance Report
(4d)
Stipple: Epitope-level precision for safer cancer therapies
(4d)
Blackstone’s Galakatos on scaling deals with $6.3B fund: ‘Broader, further’
(4d)
Industry shifts FDA from punitive to reward-based America First PDUFA policy
(5d)
Science Spotlight: Altos Labs’ cognition enhancer
(5d)
Front Row with BioCentury: Asia innovation and dealmaking beyond China
(5d)
Biogen strengthens case for BDCA2 as a cutaneous lupus target
(6d)
Tackling translation: The Parker Institute model
(6d)
With €1B fund, Jeito looks for ‘plug-and-play’ biotechs ripe for pharma takeouts
(1w)
Two $1B+ deals in 2Q26’s first week
(1w)
Gilead’s $3B Tubulis takeout to add ADC depth beyond Trodelvy
(1w)
SCRIP
AZ Optimistic On Japan Prospects Despite Pricing, LoE Challenges
(2h)
Great Expectations: Icotyde Could Be J&J’s Biggest Product Ever, Duato Says
(12h)
Obsidian Will Go Public Via Merger With Galera And Raise $350m
(12h)
Eli Lilly To Buy CrossBridge And Its Dual-Payload ADC Tech
(13h)
Evommune Makes Case For MRGPRX2 Inhibition in Migraine
(17h)
The 2026 Scrip Awards Is Open For Entries
(20h)
Travere’s Filspari Is First Drug Approved For FSGS
(21h)
Spyre Sees Monotherapy Potential For UC Drug After Phase II Data
(21h)
Belief BioMed’s Deal-Making Playbook For Chinese Rare Disease Drugs
(23h)
SynOx Charts Market Path For Emactuzumab After Phase III TGCT Win
(23h)
Ideaya Plans Accelerated Approval Filing Of Darovasertib On Positive Phase II/III Data
(1d)
Revolution’s First Phase III Daraxonrasib Data Further Boost RAS Specialist’s High Value
(1d)
Allogene Highlights Potential For Cema-Cel In The Community Setting
(1d)
Regeneron Taps Telix For Radiopharma Pact
(1d)
Quick Listen: Scrip’s Five Must-Know Things
(2d)
ADEL Raises $33M In Pre-IPO Round After Major Sanofi Deal
(2d)
GSK Bets Big On Its B7-H4 ADC With Five Phase III Trials Upcoming
(2d)
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time
(4d)
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1
(4d)
Pipeline Watch: Three Approvals And Thirteen Phase III Readouts
(4d)